News
Insights
Jobs
Career Advice
Companies
Hotbeds
More

SUBSCRIBE

SUBSCRIBE

News
Insights
Jobs
Career Advice
Companies
Hotbeds
More

Search Query

Search Results

Looking for jobs? Search jobs

11,351 Results

Type

Article (1380)
Company Profile (4)
Press Release (9967)

Section

Business (3300)
Career Advice (42)
Deals (566)
Drug Delivery (50)
Drug Development (1661)
Employer Resources (4)
FDA (449)
Job Trends (263)
News (5870)
Policy (631)

Tag

Date

Last 7 days (20)
Last 30 days (80)
Last 365 days (1064)
2025 (151)
2024 (1070)
2023 (764)
2022 (1039)
2021 (978)
2020 (916)
2019 (778)
2018 (594)
2017 (730)
2016 (536)
2015 (551)
2014 (437)
2013 (361)
2012 (395)
2011 (404)
2010 (359)

Location

Africa (20)
Asia (613)
Australia (223)
California (91)
Canada (35)
China (18)
Connecticut (9)
Europe (3082)
Florida (17)
Indiana (13)
Maryland (18)
Massachusetts (80)
Michigan (15)
New Jersey (41)
New York (10)
North Carolina (9)
Northern California (46)
Pennsylvania (23)
South America (18)
Southern California (28)
Texas (15)
Washington State (9)

Filters

Type

Article (1380)
Company Profile (4)
Press Release (9967)

Section

Business (3300)
Career Advice (42)
Deals (566)
Drug Delivery (50)
Drug Development (1661)
Employer Resources (4)
FDA (449)
Job Trends (263)
News (5870)
Policy (631)

Tag

Date

Last 7 days (20)
Last 30 days (80)
Last 365 days (1064)
2025 (151)
2024 (1070)
2023 (764)
2022 (1039)
2021 (978)
2020 (916)
2019 (778)
2018 (594)
2017 (730)
2016 (536)
2015 (551)
2014 (437)
2013 (361)
2012 (395)
2011 (404)
2010 (359)

Location

Africa (20)
Asia (613)
Australia (223)
California (91)
Canada (35)
China (18)
Connecticut (9)
Europe (3082)
Florida (17)
Indiana (13)
Maryland (18)
Massachusetts (80)
Michigan (15)
New Jersey (41)
New York (10)
North Carolina (9)
Northern California (46)
Pennsylvania (23)
South America (18)
Southern California (28)
Texas (15)
Washington State (9)

11,351 Results for "novo nordisk".

Sort By

Rare diseases

Novo’s Bispecific for Hemophilia Aces Phase III Pediatric Trial

Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III FRONTIER3 trial. The company plans to file for approval this year, hoping to compete in the hemophilia A space with Roche’s blockbuster Hemlibra.

February 7, 2025
·
2 min read
·
Dan Samorodnitsky
GLP-1

Novo Nordisk Signs $285M GLP-1 Deal With Danish Neighbor Ascendis

In a deal worth up to $285 million initially for the lead program, Novo Nordisk will gain access to Ascendis’ TransCon technology platform in an effort to find novel GLP-1 candidates with reduced dosing frequency.

November 4, 2024
·
1 min read
·
Annalee Armstrong
IRA

With Wegovy, Ozempic on the Line, Novo Asks Court to Speed Up IRA Complaint

The U.S. Centers for Medicare and Medicaid Services has named Novo Nordisk’s Wegovy, Ozempic and Rybelsus as part of the second round of the IRA drug price negotiation program, even as the pharma challenges the program.

January 29, 2025
·
1 min read
·
Tristan Manalac
GLP-1

EMA to Investigate Eye Risk for Novo’s Ozempic: Reuters

Following an appeal by the Danish Medicines Agency, the European Union’s drug regulator will review two new studies that have strengthened the link between Novo Nordisk’s blockbuster GLP-1 and a rare eye disease.

December 18, 2024
·
2 min read
·
Annalee Armstrong
Opinion

Why Is Novo Outperforming Lilly Despite Having Inferior GLP-1 Products?

Novo Nordisk’s GLP-1s outsell Eli Lilly’s thanks to its superior marketing. Here’s how.

January 3, 2025
·
6 min read
·
Gary Stibel
Layoffs

Novo Partner Omega Waves Bankruptcy Flag from Sinking Ship

Just over a year after striking an obesity deal with Novo Nordisk, an SEC filing shows Flagship Pioneering spinout Omega Therapeutics is days away from bankruptcy and will lay off up to 17 employees.

February 4, 2025
·
1 min read
·
Kate Goodwin
Legal

Novo Seeks $830M in Fraud Case Against Singaporean Biotech Over Kidney Drug

Back in 2023, Novo Nordisk committed up to $1.3 billion for a hypertension and kidney disease drug from KBP Biosciences. Now, the pharma giant claims to have been misled by the biotech’s founder—and a judge seems to agree.

February 18, 2025
·
1 min read
·
Annalee Armstrong
Earnings

Despite Doubled Wegovy Sales, Novo Executives Confront Analysts’ Insatiable Appetite

Wegovy sales increased by more than 100% over 2024. But that wasn’t enough to satiate analysts who want to know why Novo Nordisk can’t access more patients, particularly in the U.S.

February 5, 2025
·
2 min read
·
Annalee Armstrong
Diabetes

Novo Launches Citizen Petition to Block Compounded Victoza

In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide, the type 2 diabetes injection it sells as Victoza.

January 6, 2025
·
2 min read
·
Tristan Manalac
Weight loss

After Unforced Error, Novo Execs Try to Boost CagriSema Sentiment—Without Hard Numbers

Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, executives are taking another look at the data but steering clear of making hard bets.

February 7, 2025
·
3 min read
·
Annalee Armstrong

1 of 1,136

BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.

Explore
About
More

© 1985 - 2025 BioSpace.com. All rights reserved.

twitter
instagram
facebook
linkedin